Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
MDxHealth SA ADR (MDXH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: MDXH (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -44.81% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 72.02M USD | Price to earnings Ratio - | 1Y Target Price 6.04 |
Price to earnings Ratio - | 1Y Target Price 6.04 | ||
Volume (30-day avg) 98008 | Beta -413476.38 | 52 Weeks Range 1.35 - 3.50 | Updated Date 04/2/2025 |
52 Weeks Range 1.35 - 3.50 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.16 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -42.28% | Operating Margin (TTM) -18.63% |
Management Effectiveness
Return on Assets (TTM) -10.79% | Return on Equity (TTM) -345.31% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 85284620 | Price to Sales(TTM) 0.8 |
Enterprise Value 85284620 | Price to Sales(TTM) 0.8 | ||
Enterprise Value to Revenue 0.95 | Enterprise Value to EBITDA -2.73 | Shares Outstanding 49497300 | Shares Floating 32319815 |
Shares Outstanding 49497300 | Shares Floating 32319815 | ||
Percent Insiders 12.91 | Percent Institutions 45.86 |
Analyst Ratings
Rating 4.83 | Target Price 6.04 | Buy 1 | Strong Buy 5 |
Buy 1 | Strong Buy 5 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
MDxHealth SA ADR
Company Overview
History and Background
MDxHealth SA ADR was founded in 2003. It evolved from a research-focused entity to a commercial diagnostics company specializing in urological cancers.
Core Business Areas
- Urology Diagnostics: Focuses on the development and commercialization of molecular diagnostic tests for urological cancers, primarily prostate cancer.
Leadership and Structure
The company is led by a CEO and executive management team. The organizational structure includes departments for research, development, commercial operations, and finance.
Top Products and Market Share
Key Offerings
- SelectMDx for Prostate Cancer: A urine-based molecular diagnostic test that assesses a patient's risk of having clinically significant prostate cancer, helping to avoid unnecessary biopsies. Competitors include Exact Sciences (ONCO) and Genomic Health (acquired by Exact Sciences).
- ConfirmMDx for Prostate Cancer: An epigenetic test performed on prostate biopsy tissue that helps identify men at continued risk for cancer when the initial biopsy is negative. Competitors include Myriad Genetics (MYGN).
Market Dynamics
Industry Overview
The molecular diagnostics industry is growing, driven by the demand for personalized medicine and improved cancer detection and management.
Positioning
MDxHealth SA ADR is positioned as a specialized provider of urological cancer diagnostics, particularly in prostate cancer. Its competitive advantage lies in its epigenetic and molecular diagnostic technologies.
Total Addressable Market (TAM)
The global prostate cancer diagnostics market is substantial, estimated to be several billion USD. MDxHealth SA ADR is positioned to capture a share of this market through its innovative diagnostic tests.
Upturn SWOT Analysis
Strengths
- Proprietary diagnostic technologies
- Focus on urological cancers
- Established commercial presence
- Strong intellectual property portfolio
Weaknesses
- Limited product portfolio
- Reliance on reimbursement approvals
- Need for further market penetration
- Competition from larger diagnostic companies
Opportunities
- Expansion into new geographic markets
- Development of new diagnostic tests
- Partnerships with healthcare providers
- Increasing awareness of personalized medicine
Threats
- Changes in reimbursement policies
- Competition from new diagnostic technologies
- Regulatory hurdles
- Economic downturn
Competitors and Market Share
Key Competitors
- ONCO
- MYGN
Competitive Landscape
MDxHealth SA ADR competes with larger diagnostic companies. Its advantage is its focus on urological cancers and proprietary technologies, but it needs to expand its market share.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is not available in this model. Consult financial databases such as Yahoo Finance for current data.
Future Projections: Future projections are not available in this model. Consult financial databases such as Yahoo Finance for current data.
Recent Initiatives: Recent initiatives focus on expanding commercial reach, developing new diagnostic tests, and securing reimbursement approvals.
Summary
MDxHealth is a specialized urological cancer diagnostics company with proprietary technologies. Its strengths include its niche focus and established commercial presence. However, it faces challenges from larger competitors and reimbursement uncertainties. Future growth depends on expanding its market share and developing new diagnostic tests.
Similar Companies
MYGN
Myriad Genetics Inc
MYGN
Myriad Genetics Inc
ONCO
Onconetix Inc
ONCO
Onconetix Inc
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports (where available)
- Market Research Reports (where available)
Disclaimers:
The data provided is based on available information and may not be exhaustive. Market share data is estimates and may vary. Financial data should be verified with official sources.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About MDxHealth SA ADR
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-11-04 | CEO & Executive Director Mr. Michael K. McGarrity | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees - | Website https://mdxhealth.com |
Full time employees - | Website https://mdxhealth.com | ||
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. The company offers genomic prostate score which provides personalized genomic insights to both physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. It sells its products through urology sales force, consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.